How many drugs treat Hyperprolactinemia?

Drug Landscape tracks 4 marketed treatments for Hyperprolactinemia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/hyperprolactinemia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Hyperprolactinemia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hyperprolactinemia (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hyperprolactinemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Dostinex	CABERGOLINE	Pfizer Japan Inc.	Ergot Derivative [EPC]	D(2) dopamine receptor	1996-01-01
Parlodel	BROMOCRIPTINE	Esjay Pharma	Ergot Derivative	D(2) dopamine receptor	1978-01-01
Bromocriptin	Bromocriptin	University Hospital, Bonn		5-hydroxytryptamine receptor 6, Alpha-synuclein, D(1B) dopamine receptor
Dostinex	Dostinex	Par Pharmaceutical, Inc.		D(1B) dopamine receptor, D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Esjay Pharma · 1 drug in Hyperprolactinemia
Par Pharmaceutical, Inc. · 1 drug in Hyperprolactinemia
Pfizer Japan Inc. · 1 drug in Hyperprolactinemia
University Hospital, Bonn · 1 drug in Hyperprolactinemia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hyperprolactinemia:

Cite this brief

Drug Landscape (2026). Hyperprolactinemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hyperprolactinemia. Accessed 2026-06-10.

Hyperprolactinemia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing